Abstract
Background and Objective: In this mini-review, we have compiled the most recent and comparable information to shed light on the action of PEGylation in the biodistribution of carbon nanotubes (CNT) in the central nervous system (CNS). It is well known that due to the complexity of the CNS and the severity of the outcome following changes in this system, this is one of the areas where there are more investments in research to develop new technologies and approaches for more effective and less invasive treatments. The CNS is highly protected against toxic and invasive microorganisms thanks to the blood brain barrier (BBB), but this protection also prevents the passage of potentially beneficial molecules for the treatment of neurological disorders. Nanotechnology attempts to develop nanocompounds that are biocompatible and non-immunogenic, and that are able to cross the BBB in therapeutic amounts without causing damage and to diffuse through nerve tissue. These compounds should also be cleared and biodistributed properly, being capable of performing drug delivery exclusively for CNS pathologies, such as neurodegenerative diseases (Parkinson's and Alzheimer's) and brain tumors.
Conclusion: In this way, this review focuses on CNT PEGylation, aiming to help in the development of viable and effective nanomedicines for neuroscience applications.
Keywords: Biodistribution, brain, carbon nanotubes, nanotechnology, neuroscience, PEGylation.
CNS & Neurological Disorders - Drug Targets
Title:Implications of PEGylation of Carbon Nanotubes for Central Nervous System Bioavailability
Volume: 16 Issue: 9
Author(s): Gisele Eva Bruch, Marcos F. Cordeiro, Livia S. Gomides, Carolina Peixoto, Arthur P. Cordeiro, Lidiane Dal Bosco, Adelina P. Santos and Daniela M. Barros*
Affiliation:
- Laboratorio de Neurociencias, Instituto de Ciencias Biologicas, Programa de Pos-graduacao em Ciencias Fisiologicas, Universidade Federal do Rio Grande (FURG), Rio Grande, RS, 96210-900,Brazil
Keywords: Biodistribution, brain, carbon nanotubes, nanotechnology, neuroscience, PEGylation.
Abstract: Background and Objective: In this mini-review, we have compiled the most recent and comparable information to shed light on the action of PEGylation in the biodistribution of carbon nanotubes (CNT) in the central nervous system (CNS). It is well known that due to the complexity of the CNS and the severity of the outcome following changes in this system, this is one of the areas where there are more investments in research to develop new technologies and approaches for more effective and less invasive treatments. The CNS is highly protected against toxic and invasive microorganisms thanks to the blood brain barrier (BBB), but this protection also prevents the passage of potentially beneficial molecules for the treatment of neurological disorders. Nanotechnology attempts to develop nanocompounds that are biocompatible and non-immunogenic, and that are able to cross the BBB in therapeutic amounts without causing damage and to diffuse through nerve tissue. These compounds should also be cleared and biodistributed properly, being capable of performing drug delivery exclusively for CNS pathologies, such as neurodegenerative diseases (Parkinson's and Alzheimer's) and brain tumors.
Conclusion: In this way, this review focuses on CNT PEGylation, aiming to help in the development of viable and effective nanomedicines for neuroscience applications.
Export Options
About this article
Cite this article as:
Bruch Eva Gisele , Cordeiro F. Marcos, Gomides S. Livia, Peixoto Carolina , Cordeiro P. Arthur , Bosco Dal Lidiane, Santos P. Adelina and Barros M. Daniela *, Implications of PEGylation of Carbon Nanotubes for Central Nervous System Bioavailability, CNS & Neurological Disorders - Drug Targets 2017; 16 (9) . https://dx.doi.org/10.2174/1871527316666170731111735
DOI https://dx.doi.org/10.2174/1871527316666170731111735 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review on Anti-urease Potential of Coumarins
Current Drug Targets In Vivo Anticancer Activity, Toxicology and Histopathological Studies of the Thiolate Gold(I) Complex [Au(Spyrimidine)(PTA-CH<sub>2</sub>Ph)]Br
Anti-Cancer Agents in Medicinal Chemistry Insights into Ecto-5’-Nucleotidase as a New Target for Cancer Therapy: A Medicinal Chemistry Study
Current Medicinal Chemistry Use of Carbohydrate-Conjugated Nanoparticles for an Integrated Approach to Functional Imaging of Glycans and Understanding of their Molecular Mechanisms
Current Pharmaceutical Biotechnology Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors
Current Pharmaceutical Design Natural Proteinaceous Inhibitors of Serine Proteases
Current Pharmaceutical Design Investigation of Image Processing Techniques in MRI Based Medical Image Analysis Methods and Validation Metrics for Brain Tumor
Current Medical Imaging Influence of Enzyme-Inducing Antiepileptic Drugs on Trough Level of Imatinib in Glioblastoma Patients
Current Clinical Pharmacology Biocompatible Targeting Hydrogels for Breast Cancer Treatment
Mini-Reviews in Medicinal Chemistry Chemoprevention Gene Therapy (CGT) of Pancreatic Cancer Using Perillyl Alcohol and a Novel Chimeric Serotype Cancer Terminator Virus
Current Molecular Medicine The Biological Role of mTOR in the Pathogenesis of Solid Tumors: An Overview
Current Enzyme Inhibition Functional Evaluation of Imatinib mesylate in Hepatocellular Carcinoma Cells
Recent Patents on Biomarkers Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design Impact of Hybrid-polar Histone Deacetylase Inhibitor m-Carboxycinnamic Acid bis-Hydroxyamide on Human Pancreatic Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry A Fatal Case of Acute Interstitial Pneumonia (AIP) in a Woman Affected by Glioblastoma
Current Drug Safety G and C Iterons and Strings in MicroRNAs Should be Important in Regulation of mRNAs<sup>†</sup>
MicroRNA A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry Rho as a Target to Promote Repair: Translation to Clinical Studies with Cethrin
Current Pharmaceutical Design Peptide-Receptor Ligands and Multivalent Approach
Anti-Cancer Agents in Medicinal Chemistry Anticancer Potential and Molecular Targets of Pristimerin: A Mini- Review
Current Cancer Drug Targets